TCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TScan Therapeutics Inc (TCRX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, hedge fund interest, and positive technical indicators suggest potential upside. Despite the lack of news and valuation data, the improving financials and hedge fund activity make it a favorable choice for long-term investment.
The MACD is positive and expanding (0.0179), indicating bullish momentum. RSI is at 77.732, in the neutral zone, and moving averages are converging. The pre-market price is $1.14, up 2.70%, with resistance levels at $1.118 and $1.175, suggesting potential for further upward movement.
Hedge funds are significantly increasing their positions, with a 12447.81% increase in buying activity over the last quarter. Revenue growth of 139.37% YoY in Q3 2025 indicates strong operational performance.
No recent news or valuation data available. Net income remains negative at -$35.71M, though it has improved YoY.
In Q3 2025, revenue increased by 139.37% YoY to $2.51M. Net income improved by 19.48% YoY to -$35.71M. EPS improved by 12% YoY to -0.28. Gross margin remains at 100%.
No data available for analyst ratings or price target changes.
